Pemafibrate
 | |
| Clinical data | |
|---|---|
| Trade names | Parmodia |
| Other names | K-13675 |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C28H30N2O6 |
| Molar mass | 490.556 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pemafibrate, sold under the brand namd Parmodia, is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It is developed and marketed by Kowa Pharmaceuticals.[1]
In July 2017, Pharmaceuticals and Medical Devices Agency approved it in Japan.[2][failed verification]
References
[edit]- ^ Yamashita S, Masuda D, Matsuzawa Y (January 2020). "Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases". Current Atherosclerosis Reports. 22 (1): 5. doi:10.1007/s11883-020-0823-5. PMC 6978439. PMID 31974794.
- ^ Pemafibrate Archived 2018-02-05 at the Wayback Machine, pharmacodia.com
| GI tract |
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liver |
| ||||||||||||
| Blood vessels |
| ||||||||||||
| Combinations | |||||||||||||
| Other | |||||||||||||
| |||||||||||||
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
Cover photo is available under {{::mainImage.info.license.name || 'Unknown'}} license.
Cover photo is available under {{::mainImage.info.license.name || 'Unknown'}} license.
Credit:
(see original file).
